Cowin Capital

Founded 2000
Founders Alex Zheng Huang Li


Unlock datapoints

Portfolio analytics



News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 167
Average round size
The average size of a deal this fund participated in
Portfolio companies 143
Rounds per year 7.95
Lead investments 34
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 28
Key employees 3
Stages of investment
Early Stage Venture

Areas of investment

  • Health Care
  • Manufacturing
  • Electronics
  • Medical
  • Information Technology

Cowin Capital is the famous VC, which was founded in 2000. The main office of represented VC is situated in the Shenzhen. The company was established in Asia in China.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Cowin Capital, startups are often financed by Qiming Venture Partners, QF Capital, Lightspeed China Partners. The meaningful sponsors for the fund in investment in the same round are Qiming Venture Partners, Oriza Holdings, Lightspeed China Partners. In the next rounds fund is usually obtained by Matrix Partners China, Genesis Capital, Eastern Bell Venture Capital.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year. Speaking about the real fund results, this VC is 24 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2019.

This organization was formed by Alex Zheng, Huang Li.

The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular fund investment industries, there are Health Care, Clinical Trials. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the various public portfolio startups of the fund, we may underline Liking Fit, KBP Biosciences, Connect Biopharmaceuticals

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Jade Bird Display

Consumer Electronics
26 Nov 2021 Shanghai, Shanghai, China


Medical Device
$47M19 Nov 2021 China, Wuwei, China


Consumer Electronics
16 Nov 2021 Foshan, Guangdong, China


$93M01 Sep 2021 Hefei, Anhui, China


09 Aug 2021 Shanghai, Shanghai, China

I personnel

Human Resources
$15M29 Jun 2021 Shanghai, Shanghai, China


Autonomous Vehicles
$190M03 Jun 2021 Shanghai, China


$15M15 Mar 2021 Haidian District, Beijing, China


Media and Entertainment
Video Streaming
12 Mar 2021 Futian District, Guangdong Province, China
New Core Tech Raises USD 35M in Series C Funding

– New Core Tech is a Shanghai, China-based manufacturing company.
– The company raised USD 35M in Series C funding.
– The round was led by XiaoMi, Shunwei Capital with participation from Northern Light Venture Capital and Cowin Capital.
– The new investment will be used to partnership and channel expansion and talent acquisition.

Biotheus Announces the Closing of a New Round of Financing co-led by General Atlantic and IDG Capital

– Biotheus announced the completion of a fourth round of financing, co-led by General Atlantic and IDG Capital.
– New investors include Kunlun Capital, CPE, and Cowin Capital.
– Biotheus is a clinical development stage company with the mission of treating cancer and autoimmune diseases through next-generation therapeutics.
– This is supported by the company’s product pipeline, which consists of over 10 novel monoclonal and multispecific antibodies.
– Biotheus currently has two bispecific antibodies in phase I clinical development for cancer treatment, and a third IND application was submitted at the end of 2020.


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Cowin Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: